TAG:
specialty labs
“August 1, 2005 Intelligence: Late Breaking Lab News”
By Robert Michel | From the Volume XII No. 11 – August 1, 2005 Issue
Redwood City, California-based Genomic Health, Inc. is considering an initial public offering (IPO) to raise as much as $75 million. The company filed preliminary documents with the Securities and Exchange Commission (SEC) on July 15, 2005. In January 2004, Genomic H…
“May 30, 2005 Intelligence: Late Breaking Lab News”
By Robert Michel | From the Volume XII No. 8 – May 30, 2005 Issue
It’s been a revolving door for senior executives at Specialty Laboratories, Inc. during the past seven weeks. Gone by resignation is CFO Kevin Sayer (effective May 16). Gone by elimination of positions are Dan R. Angress, Sr. VP/Business Development (April 8) and Cynthia K. French,…
LabCorp Buys Esoterix For $150 Million in Cash
By Robert Michel | From the Volume XII No. 6 – April 18, 2005 Issue
CEO SUMMARY: Laboratory Corporation of America continues to display an appetite to grow by acquisition. However, its purchase of Esoterix, Inc. creates unique management problems for LabCorp, because Esoterix is itself a product of a lab acquisition strategy. Over the past ten years, Esot…
“Lowest-Priced” Chickens Came Home to Roost
By R. Lewis Dark | From the Volume XII No. 4 – March 7, 2005 Issue
IN READING THE INTELLIGENCE BRIEFINGS on reference/esoteric laboratories in this issue, I found it interesting that American Medical Laboratories (AML) is no longer an independent lab company serving this market segment and that, of the four remaining independent lab companies focuse…
Profit Squeeze Pressures Specialty Laboratories
By Robert Michel | From the Volume XII No. 4 – March 7, 2005 Issue
CEO SUMMARY: Despite much success and milestones at Specialty Laboratories during the past 36 months, it has yet to achieve the most important goal of all: net profits. One reason is familiar to all laboratory administrators and pathologists: with its existing fixed overhead and cost stru…
Bi-Annual Look at Trends Reshaping Clinical Labs
By Robert Michel | From the Volume XII No. 2 – January 24, 2005 Issue
CEO SUMMARY: Among other things, we declare the end to the heyday of the independent commercial lab company which offers a broad test menu to all types of office-based physicians. In its place springs forth the specialty or niche testing laboratory. Small and focused on a specific number …
National AP Firms Target Gastroenterology Groups
By Robert Michel | From the Volume XI No. 9 – June 28, 2004 Issue
CEO SUMMARY: It’s a trend as yet invisible to the radar screens of most pathology groups. A new crop of specialty AP companies is targeting gastroenterology. In the past 36 months, several have posted phenomenal growth in both specimen volume and revenue. The heightened competition for …
Digene, Kaiser Northern California, ARUP Labs, Bio-Reference Labs, Specialty Labs
By Robert Michel | From the Volume XI No. 9 – June 28, 2004 Issue
DIGENE ENJOYS GROWTH OF 39% IN RECENT MONTHS FUELED BY RECOGNITION that HPV plays a key role in causing cervical cancer, demand for Digene Corporation’s hc2 High-Risk HPV DNA test is increasing at impressive rates. For fiscal third quarter 2004, Digene reported revenue gr…
New Esoteric Lab Firm Does Two Acquisitions
By Robert Michel | From the Volume XI No. 6 – April 26, 2004 Issue
CEO SUMMARY: Armed with $70 million, American Esoteric Laboratories (AEL) wants to build a national laboratory that offers a full menu of esoteric tests. It is building a primary laboratory in Dallas, which has one of the nation’s best air transport hubs. ThromboCare Laboratories and Vi…
Specialty Laboratories, Cytyc, Quest Diagnostics, DakoCytomation, Abbot
By Robert Michel | From the Volume XI No. 6 – April 26, 2004 Issue
SPECIALTY LABORATORIES SHOWS VOLUME GROWTH DURING CALENDAR 2003 If the financial performance of Specialty Laboratories, Inc. in fourth quarter 2003 is an accurate measure, it appears the company has moved past its troubling problems of 2002. For fourth quarter 2003, Special…
CURRENT ISSUE

Volume XXXII, No. 6 – April 21, 2025
Now that a federal judge has vacated the FDA’s LDT rule, The Dark Report analyzes the judgement and notes the various steps the FDA could take in response. Also, lab testing at pharmacies is proving to be less successful than was once anticipated.
See the full table of contentsHow Much Laboratory Business Intelligence Have You Missed?
Lab leaders rely on THE DARK REPORT for actionable intelligence on important developments in the business of laboratory testing. Maximize the money you make-and the money you keep! Best of all, it is released every three weeks!
Sign up for TDR Insider
Join the Dark Intelligence Group FREE and get TDR Insider FREE!
Never miss a single update on the issues that matter to you and your business.
Topics
- Anatomic Pathology
- Clinical Chemistry
- Clinical Laboratory
- Clinical Laboratory Trends
- Digital Pathology
- Genetic Testing
- In Vitro Diagnostics
- IVD/Lab Informatics
- Lab Intelligence
- Lab Marketplace
- Lab Risk & Compliance
- Laboratory Automation
- Laboratory Billing
- Laboratory Compliance
- Laboratory Equipment
- Laboratory Information Systems
- Laboratory Management
- Lean Six Sigma
- Managed Care Contracts
- Molecular Diagnostics
- Pathology Trends
- People
- Uncategorized